文献速递乳房整形与再造

乳房再造相关临床试验入组患者的种族与民族差异

Racial and Ethnic Disparities Among Patients Enrolled in Breast Reconstruction-Related Clinical Trials.
PubMed 文献 · Ann Plast Surg · 2025-01-01

该研究回顾性分析了ClinicalTrials.gov上25项美国乳房再造相关临床试验共2603例患者,发现仅28%报告种族、20%同时报告种族与民族。少数族裔入组率均显著低于其乳腺癌预期负担比例,而白人入组者显著过度代表。作者认为需加强报告并主动增加少数族裔招募。

要点

  • 25项乳房再造相关临床试验中仅7项(28%)报告入组者种族,5项(20%)同时报告种族与民族。
  • 少数族裔入组比例(黑人3.5%、亚裔1.5%、美洲印第安/阿拉斯加原住民0.1%、西班牙裔/拉丁裔7.6%)均显著低于其乳腺癌预期负担比例。
  • 白人入组者占90.8%,显著高于其乳腺癌负担比例26.4%(P < 0.01)。

核心结论

  • 超过70%的乳房再造相关临床试验未报告入组者的种族或民族。
  • 在报告了种族或民族的试验中,少数族裔入组者显著代表不足,而白人入组者显著过度代表。
  • 作者认为需要更勤勉的报告和主动增加少数族裔招募的举措,以增强乳房再造相关临床试验的有效性。

研究设计与样本

  • 回顾性审查2024年2月ClinicalTrials.gov上所有已完成的、基于美国的乳房再造相关临床试验。
  • 共纳入25项研究,代表2603例患者,记录年龄、种族、民族和试验资金来源。
  • 将各race/ethnicity组的入组率与基于乳腺癌发病率计算的预期代表率进行比较,采用描述性统计和单变量分析。

主要发现

  • 入组者平均年龄为49.4 ± 2.2岁。
  • 7项(28%)研究报告了入组者种族,5项(20%)同时报告了种族和民族。
  • 大多数入组者为白人(90.8%),其次为黑人(3.5%)、亚裔(1.5%)、美洲印第安/阿拉斯加原住民(0.1%)。
  • 西班牙裔/拉丁裔入组者少于非西班牙裔/拉丁裔(7.6% vs 91.5%,P < 0.01)。
  • 少数族裔观察入组率低于各自预期代表率:黑人3.5% vs 24.9%(P < 0.01);亚裔1.5% vs 23.9%(P < 0.01);美洲印第安/阿拉斯加原住民0.1% vs 24.9%(P < 0.01);西班牙裔/拉丁裔7.6% vs 45.2%(P < 0.01)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Breast reconstruction clinical trials that reflect the racial and ethnic makeup of breast cancer disease burden are fundamental in improving breast reconstruction accessibility and outcomes. We aim to evaluate race and ethnicity reporting in breast reconstruction-related clinical trials (BRRCTs) and determine whether reported race and ethnicity of enrollees aligns with their breast cancer incidence rates in the general US population. METHODS: All completed, US-based BRRCTs were retrospectively reviewed via ClinicalTrials.gov in February 2024. Age, race, ethnicity, and BRRCT funding source were recorded. BRRCT enrollment rates of racial and ethnic groups were compared to their expected representation rates, calculated using breast cancer incidence rate. Descriptive statistics and univariate analyses were performed. RESULTS: Twenty-five studies representing 2603 patients were included. The mean age of enrollees was 49.4 ± 2.2 years. Seven (28%) reported enrollees' race, and 5 (20%) reported both race and ethnicity. Most enrollees were White (90.8%), followed by Black (3.5%), Asian (1.5%), and American Indian/Alaska Native (AI/AN) (0.1%). Fewer enrollees identified as Hispanic/Latino than non-Hispanic/Latino (7.6% vs 91.5%, P < 0.01). Observed enrollment rates of minority groups were lower than their respective expected representation rates (Black: 3.5% vs 24.9%, P < 0.01; Asian: 1.5% vs 23.9%, P < 0.01; AI/AN: 0.1% vs 24.9%, P < 0.01; Hispanic/Latino: 7.6% vs 45.2%, P < 0.01). Conversely, White enrollees were overrepresented when compared to the group's overall breast cancer burden (90.8% vs 26.4%; P < 0.01). CONCLUSIONS: Over 70% of BRRCTs did not report the race or ethnicity of enrollees. When reported, racial and ethnic minorities were significantly underrepresented in BRRCTs. More diligent reporting and proactive initiatives to increase recruitment of minority groups in clinical trials are needed to strengthen the validity of BRRCTs.

来源:Ann Plast Surg,查看原文。版权归原作者所有。

引用

  1. Kabir R, Hernandez M, Torres BS, et al. Racial and Ethnic Disparities Among Patients Enrolled in Breast Reconstruction-Related Clinical Trials. Ann Plast Surg. 2025. PMID: 40167096. doi:10.1097/SAP.0000000000004264

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。